Inactivated COVID-19 vaccines: potential concerns of antibody-dependent enhancement and original antigenic sin

Inactivated vaccine is one of the platforms employed in COVID-19 vaccines. Inactivated vaccines have been associated with concerns of antibody-dependent enhancement (ADE) and original antigenic sin (OAS), which are related to non-neutralising or poorly neutralising antibodies against the pathogen. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Kan, Andy Ka Chun, Li, Philip Hei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Immunological Societies. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205130/
https://www.ncbi.nlm.nih.gov/pubmed/37230399
http://dx.doi.org/10.1016/j.imlet.2023.05.007
Descripción
Sumario:Inactivated vaccine is one of the platforms employed in COVID-19 vaccines. Inactivated vaccines have been associated with concerns of antibody-dependent enhancement (ADE) and original antigenic sin (OAS), which are related to non-neutralising or poorly neutralising antibodies against the pathogen. Since inactivated COVID-19 vaccines use whole-SARS-CoV-2 virus as the immunogen, they are expected to generate antibodies against non-spike structural proteins, which are highly conservative across variants of SARS-CoV-2. These antibodies against non-spike structural proteins have found to be largely non-neutralising or poorly neutralising in nature. Hence, inactivated COVID-19 vaccines could possibly be associated with ADE and OAS, especially as novel variants emerge. This article explores the potential concern of ADE and OAS in the context of inactivated COVID-19 vaccine, and outlines the future research directions.

Ejemplares similares